Efficacy and Safety of Anlotinib-Containing Regimens in Advanced Non-Small Cell Lung Cancer: A Real-World Study
Lei Sun,Qi Zhao,Yanning Wang,Yongsheng Wang,Ming Zheng,Xuansheng Ding,Liyun Miao
DOI: https://doi.org/10.2147/ijgm.s424777
IF: 2.145
2023-09-13
International Journal of General Medicine
Abstract:Lei Sun, 1, &ast Qi Zhao, 2, &ast Yanning Wang, 3, &ast Yongsheng Wang, 2 Ming Zheng, 2 Xuansheng Ding, 4 Liyun Miao 2 1 School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University Nanjing Drum Tower Hospital, Nanjing, People's Republic of China; 2 Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, People's Republic of China; 3 Clinical Stem Cell Center, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, People's Republic of China; 4 School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Liyun Miao, Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, People's Republic of China, Tel +86 13813920964, Fax +86-25-68183333, Email Purpose: Anlotinib is widely used in the clinical treatment of non-small cell lung cancer (NSCLC), alone or in combination with other anticancer drugs. The aim of this study was to investigate the real-world efficacy and safety of anlotinib-containing regimens. Patients and Methods: Confirmed advanced NSCLC patients who had received anlotinib alone or in combination were enrolled. An overall analysis of the efficacy and safety of anlotinib was performed in all patients, and then subgroup analysis was used to further compare the efficacy between anlotinib monotherapy and combination therapy. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were ADR, ORR, and DCR. Results: A total of 240 patients were included. The overall median PFS was 8.5 months (95% confidence interval [CI]: 7.1– 9.9 months). Anlotinib treatment regimens (monotherapy or combination therapy) and whether they received previous antiangiogenesis were associated with PFS. Anlotinib plus immunotherapy achieved longer PFS than anlotinib monotherapy (median PFS: 10.5 vs 6.5 months, p=0.007). Stratification analysis showed the PFS of anlotinib plus immunotherapy was significantly longer in male, adenocarcinoma, <=65 years old, patients stage IV, EGFR wild type, with extrathoracic metastasis, performance status scores ≥ 2, the first-line treatment, patients with a history of hypertension and no previous antiangiogenesis than anlotinib monotherapy. The median PFS of anlotinib plus chemotherapy, targeted therapy was slightly longer than anlotinib alone (respectively, 10.5 vs 6.5 months, p=0.095; 9.5 vs 6.5 months, p=0.177). Adverse reactions were mostly mild and acceptable, with hypertension being the most common. Conclusion: Anlotinib is effective and tolerable in advanced NSCLC patients. Immunotherapy combination with anlotinib significantly improved PFS. The efficacy of anlotinib may be impaired by previous antiangiogenic therapy, which can be investigated in further studies. Keywords: non-small cell lung cancer, anlotinib, combination therapy, immunotherapy, efficacy, safety Over the last decade, lung cancer has been the leading cause of cancer-related death among all malignancies. Lung cancer caused estimated 2.2 million new cases (11.7%) and 1.8 million deaths (18%) in 2020, as the second most commonly diagnosed cancer and the highest cancer-related mortality worldwide. 1 Non-small cell lung cancer (NSCLC) accounts for approximately 83% of lung cancer cases and tends to be diagnosed at advanced stages, causing a huge mortality burden. 2 The processes of angiogenesis play crucial roles in cancer development, including NSCLC. 3,4 Antiangiogenic agents, such as multi-target tyrosine kinase inhibitors (TKIs), bevacizumab (Avastin) and recombinant human endostatin injection (endostar), can achieve therapeutic benefit in a wide range of solid tumors. 5 Anlotinib, a novel TKI that inhibits tumor angiogenesis and proliferation, was approved for monotherapy as a third and further-line treatment for advanced or metastatic NSCLC in 2018. 6–8 Anlotinib monotherapy in third and further-line NSCLC treatment showed significantly longer progression-free survival (PFS) (median PFS: 5.4 vs 1.4 months) than patients receiving placebo 9,10 At the same time, with the rise of the concept of combination therapy in the field of tumors, anlotinib is being used more widely in clinical practice. Preclinical researches and case reports demonstrated that anlotinib may modulate the tumor microenvironment and act synergist -Abstract Truncated-
medicine, general & internal